GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Principia Biopharma Inc (NAS:PRNB) » Definitions » Research & Development

Principia Biopharma (Principia Biopharma) Research & Development : $72.23 Mil (TTM As of Jun. 2020)


View and export this data going back to 2018. Start your Free Trial

What is Principia Biopharma Research & Development?

Research & Development is the aggregate amount of research and development expenses during the year. Principia Biopharma's Research & Development for the three months ended in Jun. 2020 was $20.32 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Jun. 2020 was $72.23 Mil.

Principia Biopharma Research & Development Historical Data

The historical data trend for Principia Biopharma's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Principia Biopharma Research & Development Chart

Principia Biopharma Annual Data
Trend Dec16 Dec17 Dec18 Dec19
Research & Development
15.88 18.40 28.60 48.42

Principia Biopharma Quarterly Data
Dec16 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 12.63 11.86 13.31 26.74 20.32

Principia Biopharma Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Jun. 2020 adds up the quarterly data reported by the company within the most recent 12 months, which was $72.23 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Principia Biopharma  (NAS:PRNB) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Principia Biopharma Research & Development Related Terms

Thank you for viewing the detailed overview of Principia Biopharma's Research & Development provided by GuruFocus.com. Please click on the following links to see related term pages.

Principia Biopharma (Principia Biopharma) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Principia Biopharma Inc (NAS:PRNB) » Definitions » Research & Development
Comparable Companies
TGTX TPTX INO RARX ALEC ADCT ICPT KRTX APLS ALKS OCSE:NOVO B ASX:CSL VRTX REGN XKRX:207940 SGEN MRNA ALXN XKRX:068270 INCY
Traded in Other Exchanges
N/A
Address
220 East Grand Avenue, South San Francisco, CA, USA, 94080
Website
https://www.principiabio.com
Principia Biopharma Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing novel therapies for immunology and oncology. Its proprietary Tailored Covalency platform enables to design and develop reversible and irreversible covalent small molecule inhibitors with potencies and selectivities. The company pipeline products include PRN1008 and PRN2246 and PRN1371 under BTK franchise.
Executives
Patrick Machado director 201 SPEAR STREET, 3RD FLOOR, SAN FRANCISCO CA 94107
Stefani Wolff officer: Chief Development Officer C/O PRINCIPIA BIOPHARMA INC., 400 EAST JAMIE COURT, SUITE 302, SOUTH SAN FRANCISCO CA 94080
Daniel J. Becker director C/O NEW LEAF VENTURE PARTNERS, TIMES SQ TOWER, 7 TIMES SQ, STE 3502, NEW YORK NY 10036
Martin Babler director, officer: President, CEO C/O INFINITY PHARMACEUTICALS, INC., 780 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Dolca Thomas officer: Chief Medical Officer C/O PRINCIPIA BIOPHARMA INC., 220 E. GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
Simeon George director 161 WASHINGTON STREET, SUITE 500, CONSHOHOCKEN PA 19428
Shawn Tomasello director C/O PHARMACYCLICS, INC, 995 EAST ARQUES AVENUE, SUNNYVALE CA 94085
Alan Colowick director C/O THRESHOLD PHARMACEUTICALS, INC., 1300 SEAPORT BOULEVARD, 5TH FLOOR, REDWOOD CITY CA 94063
Shao-lee Lin director C/O ACELYRIN, INC., 4149 LIBERTY CANYON RD., AGOURA HILLS CA 91301
David M Goldstein officer: Chief Scientific Officer C/O PRINCIPIA BIOPHARMA INC. 400 EAST JAMIE COURT, SUITE 302 SOUTH SAN FRANCISCO CA 94080
Roy C. Hardiman officer: Chief Business Officer C/O PHARMACYCLICS, INC. 995 EAST ARQUES AVENUE SUNNYVALE CA 94085
Christopher Y Chai officer: Chief Financial Officer 2400 BAYSHORE PARKWAY, SUITE 200, MOUNTAIN VIEW CA 94043
Biotechnology Value Fund L P other: See Explanation of Responses 44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
Bvf Gp Holdings Llc 10 percent owner 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Bvf Ii Gp Llc other: See Explanation of Responses 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104